The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses - Trial NCT06128915
Access comprehensive clinical trial information for NCT06128915 through Pure Global AI's free database. This Phase 4 trial is sponsored by State University of New York at Buffalo and is currently Not yet recruiting. The study focuses on Aging. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
State University of New York at Buffalo
Timeline & Enrollment
Phase 4
Jan 08, 2024
May 31, 2026
Primary Outcome
Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination
Summary
This study focuses on the role of neutrophils in shaping the adaptive immune response to the
 anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06128915
Non-Device Trial